Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.33 USD | -0.14% | -1.35% | +95.99% |
Mar. 21 | Fate Therapeutics, Inc. announced that it has received $19.996366 million in funding from Redmile Group, LLC | CI |
Mar. 19 | Fate Therapeutics Prices $100 Million Offering, Private Placement | MT |
Evolution of the average Target Price on Fate Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Fate Therapeutics, Inc.
Morgan Stanley | |
BMO Capital | |
Barclays | |
Wedbush | |
Mizuho Securities | |
Wells Fargo Securities | |
Stifel Nicolaus | |
Cantor Fitzgerald | |
Citigroup | |
HC Wainwright | |
Goldman Sachs | |
BofA Securities | |
EF Hutton | |
SVB Securities LLC | |
Jefferies & Co. | |
SMBC Nikko | |
Cowen | |
Piper Sandler | |
Truist Securities | |
Guggenheim | |
Oppenheimer | |
Canaccord Genuity | |
Morgan Lewins & Co. | |
Needham & Co. | |
Baird | |
SVB Leerink |
EPS Revisions
- Stock
- Equities
- Stock Fate Therapeutics, Inc. - Nasdaq
- Consensus Fate Therapeutics, Inc.